Immunovant’s Eye Disease Drug Fails Pivotal Phase 3 Trial In a significant setback for patients and the biotech company, Immunovant has announced that its investigational drug for thyroid eye disease (TED) failed to meet its primary endpoint in a crucial Phase 3 clinical trial. The news, released on April 2, 2026, sent shockwaves through the […]
Immunovant Eye Disease Drug Fails Late-Stage Trial Read More »
Sight Sciences to Showcase Glaucoma and Dry Eye Innovations at ASCRS 2026 The landscape of ophthalmic care is poised for a significant update as Sight Sciences, Inc. prepares to take center stage at the upcoming 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The company has announced that its portfolio of interventional
Sight Sciences to Present Glaucoma Tech at ASCRS 2026 Read More »
A virus once linked only to marine animals is now under investigation for causing severe eye infections in humans. Researchers uncovered the connection after several patients developed unusual eye inflammation that doctors could not explain through standard testing. The discovery raised concern among eye specialists, virologists, and public health researchers. It also exposed how little
Marine Animal Virus Linked to Strange Eye Issues Read More »
AI Eye Exams Predict Heart Disease Risk in Routine Checkups For decades, the routine eye exam has been a window to the soul of our vision health. But what if that same quick, non-invasive look could also reveal the secrets of your heart? Groundbreaking new research suggests that artificial intelligence (AI), trained to analyze scans
AI Eye Exams Detect Heart Disease Risk Early Read More »
Viridian Stock Crashes 34% After Eye Drug Efficacy Disappoints The brutal reality of biotech investing was on full display this week as Viridian Therapeutics saw its stock price plunge by a staggering 34% in a single day. The catalyst? Clinical trial results for its promising eye disease drug, VRDN-001, which delivered a paradoxical blow: it
Viridian Shares Drop 34% Despite Eye Drug Trial Success Read More »
Viridian’s Thyroid Eye Disease Drug Stumbles, Stock Plummets 30% The race to challenge Amgen’s blockbuster thyroid eye disease (TED) drug, Tepezza, just hit a major roadblock. Viridian Therapeutics, a biotech firm that had been gaining significant attention from investors, saw its stock price crater by over 30% following the release of disappointing early-stage clinical trial
Amgen Rival Plummets By A Third: What Happened Read More »
Viridian’s Elegrobart Succeeds in Phase 3 Thyroid Eye Disease Trial In a significant breakthrough for patients with Thyroid Eye Disease (TED), Viridian Therapeutics has announced positive topline results from its pivotal Phase 3 REVEAL1 clinical trial. The trial evaluated the efficacy and safety of elegrobart, the company’s novel investigational monoclonal antibody, in treating active, moderate-to-severe
Viridian Reports Positive Phase 3 Results in Thyroid Eye Read More »
Ultra-Processed Foods Linked to Heart Disease and Glaucoma Risk For years, nutritionists have urged us to “eat clean” and avoid packaged snacks and ready-made meals. Now, a powerful new study provides some of the strongest evidence yet that this advice is not just about waistlines—it’s a matter of life and death for your heart and
Ultra-Processed Foods, Heart Risk and Glaucoma Study Read More »
Kodiak Sciences’ Positive Eye Disease Data: Should Investors Buy the Rally? The biotech sector is no stranger to dramatic swings, and Kodiak Sciences Inc. (KOD) just provided a textbook example. After announcing positive topline data from its pivotal GLEAM and GLIMMER studies for its lead candidate, **tarcocimab tedromer**, in diabetic eye diseases, the company’s stock
Kodiak Sciences Shares Rise on Positive Eye Disease Data Read More »
Kodiak Sciences Stock Surges After Positive Eye Disease Trial Results In a significant development for both patients and investors, Kodiak Sciences Inc. (NASDAQ: KOD) saw its stock price rocket upwards following the announcement of highly promising Phase III clinical trial data. The biopharmaceutical company, focused on novel treatments for retinal diseases, reported that its lead
KOD Stock Rises on Phase III Eye Disease Trial Success Read More »
inquiry@glaucoma.ph
Copyright Glaucoma Philippines, ©2026
